StockNews.com initiated coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Shares of NASDAQ:ADMP opened at $0.41 on Friday. The company has a fifty day moving average of $0.49 and a 200-day moving average of $0.62. Adamis Pharmaceuticals has a 52-week low of $0.31 and a 52-week high of $1.48.
Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) last announced its quarterly earnings results on Monday, May 16th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.04). Adamis Pharmaceuticals had a negative return on equity of 100.63% and a negative net margin of 458.77%. On average, sell-side analysts anticipate that Adamis Pharmaceuticals will post -0.15 EPS for the current year.
About Adamis Pharmaceuticals (Get Rating)
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose.
- Get a free copy of the StockNews.com research report on Adamis Pharmaceuticals (ADMP)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.